Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma.

Pisklakova A, McKenzie B, Zemp F, Lun X, Kenchappa RS, Etame AB, Rahman MM, Reilly K, Pilon-Thomas S, McFadden G, Kurz E, Forsyth PA.

Neuro Oncol. 2016 Mar 8. pii: now006. [Epub ahead of print]

2.

Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.

Zemp FJ, Lun X, McKenzie BA, Zhou H, Maxwell L, Sun B, Kelly JJ, Stechishin O, Luchman A, Weiss S, Cairncross JG, Hamilton MG, Rabinovich BA, Rahman MM, Mohamed MR, Smallwood S, Senger DL, Bell J, McFadden G, Forsyth PA.

Neuro Oncol. 2013 Jul;15(7):904-20. doi: 10.1093/neuonc/not035. Epub 2013 Apr 12.

3.

In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.

McKenzie BA, Zemp FJ, Pisklakova A, Narendran A, McFadden G, Lun X, Kenchappa RS, Kurz EU, Forsyth PA.

Neuro Oncol. 2015 Aug;17(8):1086-94. doi: 10.1093/neuonc/nou359. Epub 2015 Jan 20.

4.

Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.

Ogbomo H, Zemp FJ, Lun X, Zhang J, Stack D, Rahman MM, McFadden G, Mody CH, Forsyth PA.

PLoS One. 2013 Jun 10;8(6):e66825. doi: 10.1371/journal.pone.0066825. Print 2013.

5.

Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.

Zemp FJ, McKenzie BA, Lun X, Reilly KM, McFadden G, Yong VW, Forsyth PA.

Cancer Res. 2014 Dec 15;74(24):7260-73. doi: 10.1158/0008-5472.CAN-14-0876. Epub 2014 Oct 21.

6.

Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.

Zemp FJ, McKenzie BA, Lun X, Maxwell L, Reilly KM, McFadden G, Yong VW, Forsyth PA.

PLoS One. 2013 Jun 6;8(6):e65801. doi: 10.1371/journal.pone.0065801. Print 2013. Erratum in: PLoS One. 2014;9(6):e101827.

7.

Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo.

Weng M, Gong W, Ma M, Chu B, Qin Y, Zhang M, Lun X, McFadden G, Forsyth P, Yang Y, Quan Z.

Mol Cancer. 2014 Apr 13;13:82. doi: 10.1186/1476-4598-13-82.

8.

Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity.

Tosic V, Thomas DL, Kranz DM, Liu J, McFadden G, Shisler JL, MacNeill AL, Roy EJ.

PLoS One. 2014 Oct 16;9(10):e109801. doi: 10.1371/journal.pone.0109801. eCollection 2014.

9.

Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.

Lun X, Alain T, Zemp FJ, Zhou H, Rahman MM, Hamilton MG, McFadden G, Bell J, Senger DL, Forsyth PA.

Cancer Res. 2010 Jan 15;70(2):598-608. doi: 10.1158/0008-5472.CAN-09-1510. Epub 2010 Jan 12.

10.

Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells.

Barrett JW, Alston LR, Wang F, Stanford MM, Gilbert PA, Gao X, Jimenez J, Villeneuve D, Forsyth P, McFadden G.

J Neurovirol. 2007 Dec;13(6):549-60.

PMID:
18097886
11.

Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.

Wennier ST, Liu J, Li S, Rahman MM, Mona M, McFadden G.

Mol Ther. 2012 Apr;20(4):759-68. doi: 10.1038/mt.2011.293. Epub 2012 Jan 10.

12.

Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.

Lun X, Chan J, Zhou H, Sun B, Kelly JJ, Stechishin OO, Bell JC, Parato K, Hu K, Vaillant D, Wang J, Liu TC, Breitbach C, Kirn D, Senger DL, Forsyth PA.

Mol Ther. 2010 Nov;18(11):1927-36. doi: 10.1038/mt.2010.183. Epub 2010 Aug 31.

13.

Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.

Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Nov 15;20(22):5756-67. doi: 10.1158/1078-0432.CCR-13-3389. Epub 2014 Oct 14.

14.

Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor.

Lilly CL, Villa NY, Lemos de Matos A, Ali HM, Dhillon JS, Hofland T, Rahman MM, Chan W, Bogen B, Cogle C, McFadden G.

Mol Ther Oncolytics. 2016 Dec 14;4:31-40. doi: 10.1016/j.omto.2016.12.002. eCollection 2017 Mar 17.

15.

Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits.

Liu J, Wennier S, Reinhard M, Roy E, MacNeill A, McFadden G.

J Virol. 2009 Jun;83(11):5933-8. doi: 10.1128/JVI.00204-09. Epub 2009 Mar 11.

16.

Myxoma virus oncolytic efficiency can be enhanced through chemical or genetic disruption of the actin cytoskeleton.

Irwin CR, Favis NA, Agopsowicz KC, Hitt MM, Evans DH.

PLoS One. 2013 Dec 31;8(12):e84134. doi: 10.1371/journal.pone.0084134. eCollection 2013.

17.

Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma.

Doty RA, Liu J, McFadden G, Roy EJ, MacNeill AL.

Oncolytic Virother. 2013 Jan;2:1-17.

18.

Apoptosis-inducing effect of myxoma virus on human neuroglioma cell lines.

Zhang QS, Zhang M, Huang XJ, Liu XJ, Li WP.

Exp Ther Med. 2017 Jul;14(1):344-348. doi: 10.3892/etm.2017.4487. Epub 2017 May 22.

19.

Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor.

Opgenorth A, Graham K, Nation N, Strayer D, McFadden G.

J Virol. 1992 Aug;66(8):4720-31.

20.

M062 is a host range factor essential for myxoma virus pathogenesis and functions as an antagonist of host SAMD9 in human cells.

Liu J, Wennier S, Zhang L, McFadden G.

J Virol. 2011 Apr;85(7):3270-82. doi: 10.1128/JVI.02243-10. Epub 2011 Jan 19.

Supplemental Content

Support Center